Search results for "OTR"

showing 10 items of 6791 documents

Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1.

2005

The G protein coupling characteristics of a flag epitope-tagged orexin receptor type 1 (OX1R) was investigated in HEK293 cells. Immunoprecipitation of the OX1R and immunoblotting revealed interactions with Gq/G11 proteins as well as with Gs and Gi proteins. Stimulation with orexin-A did not affect the ability of the OX1R to coprecipitate Gq/G11 proteins, but it robustly elevated the intracellular concentration of Ca2+, [Ca2+]i. No changes in cAMP levels could be detected upon receptor stimulation. To get further insight into the functional correlation of G protein activation and Ca2+ signalling, we used baculovirus transduction to express chimeric G proteins, containing the Galphas protein …

AgonistReceptors Neuropeptidemedicine.drug_classG proteinBiologyKidneyBiochemistryCell LineReceptors G-Protein-CoupledGTP-binding protein regulatorsGTP-Binding ProteinsOrexin ReceptorsTransduction GeneticMuscarinic acetylcholine receptormedicineCyclic AMPHumansCalcium SignalingPharmacologyReceptor Muscarinic M3Neurotransmitter AgentsOrexinsDose-Response Relationship DrugNeuropeptidesIntracellular Signaling Peptides and ProteinsMuscarinic acetylcholine receptor M3Fusion proteinOrexin receptorCell biologyBiochemistryCalciumSignal transductionBaculoviridaeSignal TransductionBiochemical pharmacology
researchProduct

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

2020

Abstract Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, thereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerative diseases other than MS, such as Alzheimer’s disease or epilepsy. Fingolimo…

AgonistSphingosine 1 Phosphate Receptor ModulatorsMultiple Sclerosismedicine.drug_classDrug Evaluation PreclinicalDiseaseReview ArticleRM1-950PharmacologyNeuroprotection03 medical and health sciencesEpilepsyMice0302 clinical medicineNeurotrophic factorsAlzheimer DiseasemedicineAnimalsHumansLymphocytes030304 developmental biologyPharmacology0303 health sciencesEpilepsyMicrogliabusiness.industryFingolimod HydrochlorideMultiple sclerosisAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseFingolimod3. Good healthRatsDisease Models Animalmedicine.anatomical_structureNeuroprotective AgentsTherapeutics. PharmacologyNervous System Diseasesbusiness030217 neurology & neurosurgerymedicine.drugDrugs in R&D
researchProduct

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

1999

Previous studies have established the presence of an extrahypothalamic GnRH in a variety of tissues. GnRH receptor is known to be present in the placenta, which produces and secretes the decapeptide from the very early stages of placentation. We hypothesized that GnRH may play a role in the preimplantation development of embryos. To examine this hypothesis, we assessed GnRH and GnRH receptor messenger RNA (mRNA; RT-PCR) and protein expression (Immunohistochemistry) in preimplantation murine embryos at various developmental stages. Furthermore, preimplantation murine embryos were cultured with GnRH agonist and antagonist in vitro to assess the influence of GnRH analogs on embryo development.…

Agonistendocrine systemmedicine.medical_specialtyanimal structuresTranscription Geneticmedicine.drug_classZygoteMice Inbred StrainsGonadotropin-releasing hormoneBiologyMorulaGonadotropin-Releasing HormoneEmbryonic and Fetal DevelopmentMiceEndocrinologyInternal medicinePlacentamedicineAnimalsBlastocystRNA MessengerMessenger RNAReverse Transcriptase Polymerase Chain ReactionEmbryogenesisPlacentationGene Expression Regulation DevelopmentalEmbryoEndocrinologymedicine.anatomical_structureBlastocystembryonic structureshormones hormone substitutes and hormone antagonistsReceptors LHRHEndocrinology
researchProduct

Activation of phospholipases C and D by the novel metabotropic glutamate receptor agonist tADA.

1997

Abstract In hippocampal slices taken from 8-day-old rats, trans-azetidine-2,4-dicarboxylic acid (tADA), a novel glutamatergic agonist acting preferentially at class I mGluR receptors, activates phosphoinositide and phosphatidylcholine hydrolysis with widely different potencies. Inositol phosphate formation was maximally increased at 10 μM tADA ( ec 50: 1.2 μM), while phospholipase D activation was observed at a tADA concentration of 1 mM. This is the first report of a tADA-induced phospholipase D activity. © 1997 Elsevier Science Ltd. All rights reserved.

Agonistmedicine.drug_classInositol PhosphatesPhospholipaseBiologyIn Vitro TechniquesReceptors Metabotropic GlutamateHippocampusRats Sprague-DawleyCellular and Molecular NeurosciencemedicineExcitatory Amino Acid AgonistsPhospholipase DPhospholipase D activityAnimalsInositol phosphatePharmacologychemistry.chemical_classificationPhospholipase CPhospholipase DRatsEnzyme ActivationMetabotropic receptorBiochemistrychemistryMetabotropic glutamate receptorType C PhospholipasesAzetidinecarboxylic AcidNeuropharmacology
researchProduct

Modulatory effects of the novel TrkB receptor agonist 7,8-dihydroxyflavone on synaptic transmission and intrinsic neuronal excitability in mouse visu…

2013

7,8-Dihydroxyflavone (7,8 DHF) is a new recently identified TrkB receptor agonist, which possesses a potent neurotrophic activity and shares many physiological properties with the neurotrophin "Brain Derived Neurotrophic Factor" (BDNF). However, its precise mechanism of action at the cellular level has not been clarified yet. In the present study we explored the effects of this agent on synaptic and intrinsic neuronal properties by performing whole-cell patch clamp recordings from layer 2/3 pyramidal neurons. Incubation of acute cortical slices with 7,8-DHF (20 µM) for 30 min caused a selective reduction in the strength of GABAergic inhibition. The amplitude of evoked inhibitory postsynapti…

Agonistmedicine.drug_classNerve Tissue ProteinsTropomyosin receptor kinase BNeurotransmissionIn Vitro Techniques78-DihydroxyflavoneInhibitory postsynaptic potentialSynaptic TransmissionGlutamatergicMicemedicineElectric ImpedanceAnimalsReceptor trkBGABA-A Receptor AntagonistsGABAergic NeuronsProtein Kinase InhibitorsCells CulturedNootropic AgentsVisual CortexPharmacologyBrain-derived neurotrophic factorbiologyPyramidal CellsNeural InhibitionFlavonesReceptors GABA-AMice Inbred C57BLKineticsNeuroprotective Agentsbiology.proteinEvoked Potentials VisualNeuroscienceNeurotrophinEuropean journal of pharmacology
researchProduct

Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells.

1998

Primary cultures of human bronchial epithelial cells (HBE-cells) were established to measure granulocyte-macrophage colony stimulating factor (GM-CSF) release. HBE-cells showed a basal GM-CSF release (82+/-20 ng/well/24 h; 30 donors), which was increased by interleukin-1 beta(IL-1beta, 1 ng/ml) by 270%. This effect was blocked by 1 microM dactinomycin or 10 microM cycloheximide, i.e. the stimulatory effect of IL-1beta depended on de-novo synthesis. Histamine (100 microM) and acetylcholine ( 100 nM) stimulated GM-CSF release more than two-fold above the baseline. Nicotine (1 microM) increased GM-CSF release to a similar extent, and this effect was prevented by 30 microM (+)-tubocurarine. The…

Agonistmedicine.medical_specialtyNicotinemedicine.drug_classSubstance PBronchiCycloheximideBiologyNicotinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansNicotinic AgonistsCells CulturedPharmacologyGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineAcetylcholineEndocrinologychemistryHistamineAcetylcholinemedicine.drugHistamineNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

GABA, receptor mediated fast synaptic inhibition in the rabbit brain-stem respiratory system

1991

The involvement of GABA mediated neurotransmission in the central control of respiration was investigated by administration of the specific GABAA receptor agonist muscimol and the specific GABAA receptor antagonist biculline into the fourth cerebral ventricle of the rabbit. Cycle-triggered averaging of the phrenic nerve activity (PNA) was used to quantify drug-induced changes of the central respiratory pattern. Muscimol reduced the peak amplitude of PNA and increased the duration of the respiratory phases. High amounts of muscimol led to a long-lasting but reversible central apnea. Bicuculline very effectively blocked the effects of externally applied muscimol. Blockade of intrinsically act…

Agonistmedicine.medical_specialtyPhysiologymedicine.drug_classIn Vitro TechniquesBiologyNeurotransmissionBicucullineSynaptic Transmissionchemistry.chemical_compoundInternal medicinemedicineAnimalsRespiratory systemInjections IntraventricularGallamine TriethiodideMuscimolGABAA receptorRespirationmusculoskeletal neural and ocular physiologyRespiratory centerNeural InhibitionRespiratory CenterBicucullineReceptors GABA-APhrenic NerveEndocrinologynervous systemMuscimolchemistryControl of respirationSynapsesRabbitsNeurosciencemedicine.drugActa Physiologica Scandinavica
researchProduct

Biogenic Amines Modulate Olfactory Receptor Neurons Firing Activity in Mamestra brassicae

2001

The modulatory effects of the biogenic amines octopamine and serotonin on pheromonal receptor neurons of Mamestra brassicae were investigated. The responses to sex pheromone components of two cells types (A and B) in single male long sensilla trichodea were monitored. Cell types A and B do not respond to the same compound. The response of type A to a pulse of the major sex pheromone component increased 5 min after octopamine injection. Responses of type B to other odorants increased after 30 min. In the absence of any pheromone stimulation the background firing activity of type A increased following octopamine injection. This background activity was used to evaluate the kinetics of octopami…

Agonistmedicine.medical_specialtyTime FactorsPhysiologymedicine.drug_classAgonist-antagonistMothsBiologySensory receptorClonidineOlfactory Receptor NeuronsBehavioral Neurosciencechemistry.chemical_compoundPhysiology (medical)Internal medicineBiogenic aminemedicineAnimalsAminesSex AttractantsNeurotransmitterOctopamineComputingMilieux_MISCELLANEOUSchemistry.chemical_classificationOlfactory receptorDose-Response Relationship Drug[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeuroscienceOctopamine (drug)Sensory Systemsmedicine.anatomical_structureEndocrinologychemistry[ SCCO.NEUR ] Cognitive science/NeuroscienceSerotoninChemical Senses
researchProduct

α7 Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus

2000

The present report provides new findings regarding modulation of gamma-aminobutyric acid (GABA) transmission by alpha7 nicotinic receptor activity in CA1 interneurons of rat hippocampal slices. Recordings were obtained from tight-seal cell-attached patches of the CA1 interneurons, and agonists were delivered to the neurons via a modified U-tube. Application for 6 s of the alpha7 nicotinic receptor-selective agonist choline (or =1 mM) to all CA1 interneurons tested triggered action potentials that were detected as fast current transients. The activity triggered by choline terminated well before the end of the agonist pulse, was blocked by the alpha7 nicotinic receptor antagonist methyllycaco…

Agonistmedicine.medical_specialtyalpha7 Nicotinic Acetylcholine ReceptorInterneuronmedicine.drug_classAction PotentialsIn Vitro TechniquesReceptors NicotinicBiologyHippocampusSynaptic TransmissionCholinechemistry.chemical_compoundGanglion type nicotinic receptorInterneuronsInternal medicinemedicineAnimalsNeurotransmittergamma-Aminobutyric AcidPharmacologyMethyllycaconitineDose-Response Relationship DrugRatsElectrophysiologyEndocrinologymedicine.anatomical_structureNicotinic agonistchemistryBiophysicsAlpha-4 beta-2 nicotinic receptorAcetylcholinemedicine.drugEuropean Journal of Pharmacology
researchProduct

GABAA agonist muscimol ameliorates learning/memory deficits in streptozocin-induced Alzheimer’s disease non-transgenic rat model

2015

Background: GABAergic inhibitory action regulates learning/memory processes and contributes to neurotransmission (Gong et al., 2009). Existing evidence suggests GABAergic system is involved in pathophysiology of Alzheimer’s disease (AD) via inhibitory interneuron deficits (Verret et al., 2012) and decrease in functional GABAA receptors (Limon et al., 2012). In vitro, GABA and muscimol (GABAA receptor agonist) blocked neuronal death induced by Aβ in rat hippocampal and cortical neurons (Paula-Lima et al., 2005). Our concept: low doses of muscimol may prevent learning/memory deficits in intracerebroventricular (icv) streptozocin (STZ)-induced AD non-transgenic rat model. Methods. Wistar male …

Agonistmedicine.medical_specialtymedicine.drug_class02 engineering and technologyWater mazeNeurotransmissionHippocampal formationInhibitory postsynaptic potential030226 pharmacology & pharmacymemory03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicineMultidisciplinarybusiness.industryGABAA receptorstreptozocin021001 nanoscience & nanotechnologymuscimol3. Good healthEndocrinologynervous systemMuscimolchemistryAnesthesiaPoster PresentationGABAergic0210 nano-technologybusinessSpringerPlus
researchProduct